cookiebaker
Very helpful member
- Joined
- Jul 26, 2022
- Messages
- 808
- Reason
- DX FIBRO
- Diagnosis
- 07/2022
- Country
- US
- State
- WI
so, in other words... they have no clue yet.This article from 2020 Current and Emerging Pharmacotherapy for Fibromyalgia
doesn't mention nortriptyline, can't see why, and mentions
Reboxetine (only case reports) Esreboxetine (1 trial) Nal trexone (1 trial; if depression) (1 trial) Nabilone, Dronabinol & Memantine (all with conflicting results) Ketamine (1 trial) and the newcomer is...... "NYX-2925" (works in rats).
That's where pharma research is going...
Much more interesting I found the last bit, the conclusion and expert opinion. Saying: there has been great progress in inflammatory and autoimmune disorders, but CNS conditions like fibro are baffling everyone, so experts are going to have to network. They don't think it's likely that there will be much progress in the med types currently used. One hope is to sort and treat patients based on their individual genetic (and pharmacogenetic) characteristics, plus analysis of the pathways bits of the brain connect to one another (connectivity). Another, associated to this connectivity is how the endocannabinoid system works, which is much researched now, and will help develop meds with precisely measured quantities of cannabinoid agents such as THC and CBD(!) Understanding neuroinflammation may also help (see na ltrexone, which is in L D N). Lastly they stress that managing FMS most definitely will always be more than meds, namely tools "ranging from exercise to neurofeedback and all that lie in between. Thus is the art of treating FMS." Yeah.